Therapeutic agents targeting 5-HT signaling, including direct 5-HT receptor modulators and 5-HT selective reuptake inhibitors, have been investigated as treatment options, achieving moderate efficacy in certain patients with IBS [14]. Here, HTR5A is linked to irritable bowel syndrome.